InsidersTradesSigma
Track the Boston Scientific CORP share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Boston Scientific CORP has logged 555 insider filings. Market capitalisation: €72.3bn. The latest transaction was filed on 26 August 2026 (Acquisition). Among the most active insiders: Fitzgerald Joseph Michael. All data is free.
555
Insider Decl.
n/a
Thresholds
€10m
13 ops.
Buy Volume
€90m
106 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Boston Scientific CORP Buy (bullish), based on 29 analysts. Average price target: US$62.69.
52Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 8,286 of 29,055 companies
62.2
score / 100
Value53
Quality72
FCF yld4.9%
Earn yld4.1%
EV/EBITDA16.0x
ROE15%
Gross mgn69%
Net mgn14%
Debt/EBITDA2.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 26 August 2026
Declarations555 total
2,040 shares@ US$49.2195Common StockSEC:0001225208-26-007337:0
Canonical exit: 23 Nov 2026 (T+90)
2,930 shares@ US$51.190.0002% mcap17.3% of flowCommon StockSEC:0001225208-26-007084:0
9,908 shares@ US$50.460.0007% mcap46.9% of flowCommon StockSEC:0001225208-26-007062:0
2,100 shares@ US$47.5890.0001% mcap24.6% of flowCommon StockSEC:0001225208-26-007031:0
Canonical exit: 3 Nov 2026 (T+90)
140 shares@ US$48.58790.0000% mcap2.2% of flowCommon StockSEC:0001225208-26-006951:1
Canonical exit: 2 Nov 2026 (T+90)
186,240 shares@ US$48.33230.013% mcap12.9% of flowCommon StockSEC:0001225208-26-006950:0
Canonical exit: 1 Nov 2026 (T+90)
22,119 shares@ US$48.430.0015% mcap1.5% of flowCommon StockSEC:0001225208-26-006950:1
1,042 shares@ US$48.06550.0001% mcap16.4% of flowCommon StockSEC:0001225208-26-006951:0
Canonical exit: 1 Nov 2026 (T+90)
5,000 shares@ US$45.47990.0003% mcap11.0% of flowCommon StockSEC:0001225208-26-006882:0
Canonical exit: 29 Oct 2026 (T+90)
64,198 shares@ US$46.730.0043% mcap7.5% of flowCommon StockSEC:0001225208-26-006881:0
2,087 sharesCommon StockSEC:0001225208-26-006362:0
1,010 sharesCommon StockSEC:0001225208-26-006362:1
386,755 shares0Common StockSEC:0001225208-26-005670:0
2,250 shares@ US$55.91950.0002% mcap50.1% of flowCommon StockSEC:0001225208-26-005546:1
Canonical exit: 18 Aug 2026 (T+90)
3,580 shares@ US$56.680.0003% mcap14.1% of flowCommon StockSEC:0001225208-26-005547:0
Canonical exit: 18 Aug 2026 (T+90)
1,770 shares@ US$56.490.0001% mcap100.0% of flowCommon StockSEC:0001225208-26-005548:0
Canonical exit: 18 Aug 2026 (T+90)
2,200 shares@ US$56.94510.0002% mcap49.9% of flowCommon StockSEC:0001225208-26-005546:0
Canonical exit: 17 Aug 2026 (T+90)
24 shares0Common StockSEC:0001225208-26-003179:0
556 shares0Common StockSEC:0001225208-26-003178:0
838 shares0Common StockSEC:0001225208-26-003014:0
6,851 shares@ US$75.768.0% of flowCommon StockSEC:0001225208-26-002794:0
1,413 shares0Common StockSEC:0001225208-26-002139:0
588 shares0Common StockSEC:0001225208-26-002138:0
500 shares0Common StockSEC:0001225208-26-002137:0
1,766 shares0Common StockSEC:0001225208-26-002136:0
25 of 555 declarations
关于 Boston Scientific CORP
Boston Scientific Corp. 是一家全球医疗技术公司，在美国纽约证券交易所（NYSE）上市，股票代码为BSX。对于法语投资者而言，这是一家医疗保健领域的大盘股，受益于人口老龄化、慢性病增加以及微创护理持续创新等结构性吸引力终端市场。该公司于1979年在马萨诸塞州沃特敦成立，目前全球总部位于美国马萨诸塞州马尔堡。其企业身份围绕介入医学建立，战略重点是差异化技术和临床利基市场，在这些市场中，产品创新、医生采纳和监管批准构成了重要的进入壁垒。（[bostonscientific.com](https://www.bostonscientific.com/content/dam/bostonscientific/corporate/annual-report/2024-annual-report-and-10-K.pdf.coredownload.pdf?utm_source=openai)） Boston Scientific 通过两个主要部门报告：医疗外科（MedSurg）和心血管（Cardiovascular）。其产品组合涵盖电生理学和心律管理、左心耳封堵、冠状动脉和外周介入、内窥镜、泌尿学和神经调节，以及某些微创手术解决方案。这种多元化使公司具有弹性，并通过成熟特许经营权和新兴平台的组合支持高于平均水平的增长。主要产品系列包括WATCHMAN、FARAPULSE、EKOS、EMBLEM MRI S-ICD以及广泛的内窥镜和泌尿系统。（[news.bostonscientific.com](https://news.bostonscientific.com/interested-in-our-q4-2024-financial-results?utm_source=openai)） 从竞争角度来看，Boston Scientific 在植入式和介入式医疗设备领域位居全球领先地位，与Medtronic、Abbott、Johnson & Johnson 和Edwards 等公司在不同终端市场展开竞争。其优势来自于产品组合的扩展、强大的创新引擎以及在医院、电生理学家、介入心脏病专家、胃肠病学家和泌尿科医生之间的严谨商业执行。该集团还拥有广泛的国际业务，销售遍及多个地区，并在全球多个地点设有制造和组装能力。（[bostonscientific.com](https://www.bostonscientific.com/content/dam/bostonscientific/corporate/annual-report/2024-annual-report-and-10-K.pdf.coredownload.pdf?utm_source=openai)） 近期发展进一步证实了这一论点。Boston Scientific 报告2026年第一季度净销售额为5.203 billion美元，同比增长11.6%，2025年第四季度销售额为5.286 billion美元，2025年全年营收达到20.074 billion美元。该公司还发布了FARAPULSE 和WATCHMAN 的积极临床数据，获得了多项产品的FDA 批准和许可，并宣布了包括Bolt Medical 在内的收购。对于投资者而言，BSX 仍然是一支高质量的医疗保健/制药股票，它结合了有机增长、创新和投资组合杠杆，并在一个流动性强、备受关注的美国股票市场上市。（[news.bostonscientific.com](https://news.bostonscientific.com/2026-04-22-Boston-Scientific-announces-results-for-first-quarter-2026?utm_source=openai)）
